In yet another example of industry’s growing interest in orphan drugs, a small Texas startup secured an impressive Series A to ramp up its work on a treatment for a rare disease called CTD. Life science investors Sante Ventures and New Enterprise Associates co-led the $14 million Series A for Lumos Pharma, which is repurposing […]
Raili Kerppola had a thriving career in the pharmaceutical industry when she was diagnosed with stage four adrenal cancer in 2011. While seeking treatment at the University of Michigan, she began working with an endocrinologist named Dr. Gary Hammer and her husband, a professor of biological chemistry at UM, on researching and discovering new treatments […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Clinical trials today cost 60 percent more than they did just five years ago, according to a new analysis by Cutting Edge Research. While late-stage trials generally cost the most (the average Phase 3b trial costs more than $48,000 per patient), the research firm’s analysis suggests that per-patient costs in later-stage trials leveled off in […]
It’s been nearly two-and-a-half decades since the gene associated with the inherited disease cystic fibrosis was discovered, paving the way for disease-modifying drugs. In that time, only one such drug has been approved in the U.S. and Europe — Vertex’s Kalydeco. And that drug is only approved for the 4 percent of CF patients who […]
An experimental drug being developed by Milo Biotechnology for the treatment of certain neuromuscular diseases has been given orphan drug designation by the U.S. Food and Drug Administration. The Cleveland company’s drug candidate, AAV1-FS344, is a gene delivery therapy that’s designed to produce follistatin, a protein associated with muscle size and strength, in patients with […]
A liver cancer drug being developed by a joint venture between Cleveland BioLabs (NASDAQ:CBLI) and a Russian-based venture fund was granted orphan drug status by the U.S. Food and Drug Administration this week. Curaxin CBL0102, an oral treatment for hepatocellular carcinoma, is currently being evaluated in phase 1 clinical trials in Russia. The most common […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.